A new trading day began on Monday, with Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) stock price down -0.75% from the previous day of trading, before settling in for the closing price of $0.08. ADAP’s price has ranged from $0.08 to $1.35 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 26.53% over the past five years. Meanwhile, its annual earnings per share averaged -60.00%. With a float of $229.65 million, this company’s outstanding shares have now reached $257.85 million.
Let’s look at the performance matrix of the company that is accounted for 506 employees. In terms of profitability, gross margin is 98.06%, operating margin of -36.31%, and the pretax margin is -38.17%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adaptimmune Therapeutics Plc ADR is 10.94%, while institutional ownership is 29.90%. The most recent insider transaction that took place on Jul 28 ’25, was worth 3,817,321. In this transaction 10% Owner of this company sold 33,931,740 shares at a rate of $0.11, taking the stock ownership to the 130,492,680 shares. Before that another transaction happened on Jul 30 ’25, when Company’s 10% Owner sold 27,433,338 for $0.10, making the entire transaction worth $2,800,944. This insider now owns 100,371,882 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -60.00% per share during the next fiscal year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Here are Adaptimmune Therapeutics Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.14 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) saw its 5-day average volume 61.96 million, a positive change from its year-to-date volume of 4.3 million. As of the previous 9 days, the stock’s Stochastic %D was 2.03%.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 2.04%, which indicates a significant decrease from 2.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0222 in the past 14 days, which was lower than the 0.0267 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2479, while its 200-day Moving Average is $0.4538.
